Getinge AB : Getinge Group: Year-End Report 2013

Regulatory News:

Getinge AB (STO:GETIB)

Reporting period January - December

· Order intake rose 4.0% to SEK 25,395 M (24,416) and grew organically by 4.0%

· Net sales increased 4.3% to SEK 25,287 M (24,248), corresponding to organic growth of 4.2%

· Profit before tax declined 8.2% to SEK 3,153 M (3,436)

· Net profit decreased 9.3% to SEK 2,295 M (2,531)

· Earnings per share declined 9.4% to SEK 9.59 (10.58)

· EBITA before restructuring decreased 1.7% to SEK 4,766 M (4,849). Adjusted for exchange-rate effects and the medical device tax introduced in the US, EBITA rose 8.3%

· A dividend per share of SEK 4.15 (4.15) is proposed, corresponding to SEK 989 M (989)

Reporting period October - December

· Order intake rose 4.2% to SEK 6,931 M (6,648), and grew organically by 5.9%

· Net sales declined 0.8% to SEK 7,757 M (7,816), corresponding to organic growth of 1.3%

· Profit before tax increased 18.1% to SEK 1,709 M (1,447)

· EBITA before restructuring increased 6.1% to SEK 2,062 M (1,943). Adjusted for exchange-rate effects and the medical device tax introduced in the US, EBITA rose 14.0%

· The acquisition of Pulsion Medical Systems is expected to be completed in the first quarter of 2014

Order intake

The Group's order intake posted a favorable trend for the quarter and grew organically by 5.9%. Accordingly, for the full-year 2013, order intake increased organically by 4.0%, a figure that compares favorably with other global medical technology companies.

This information was brought to you by Cision http://news.cision.com

Getinge Group
Johan Malmquist
CEO
Tel: [phone]
E-mail: [e-mail]